Consensus treatments for moderate juvenile dermatomyositis: Beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference

Adam M. Huber, Angela B. Robinson, Ann M. Reed, Leslie Abramson, Sharon Bout-Tabaku, Ruy Carrasco, Megan Curran, Brian M. Feldman, Harry Gewanter, Thomas Griffin, Kathleen Haines, Mark F. Hoeltzel, Josephine Isgro, Philip Kahn, Bianca Lang, Patti Lawler, Bracha Shaham, Heinrike Schmeling, Rosie Scuccimarri, Michael ShishovElizabeth Stringer, Julie Wohrley, Norman Todd Ilowite, Carol Wallace

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Objective. To use consensus methods and the considerable expertise contained within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) organization to extend the 3 previously developed treatment plans for moderate juvenile dermatomyositis (DM) to span the full course of treatment. Methods. A consensus meeting was held in Chicago on April 23-24, 2010, involving 30 pediatric rheumatologists and 4 lay participants. Nominal group technique was used to achieve consensus on treatment plans that represented typical management of moderate juvenile DM. A preconference survey of CARRA, completed by 151 (56%) of 272 members, was used to provide additional guidance to the discussion. Results. Consensus was reached on timing and rate of steroid tapering, duration of steroid therapy, and actions to be taken if patients were unchanged, worsening, or experiencing medication side effects or disease complications. Of particular importance, a single consensus steroid taper was developed. Conclusion. We were able to develop consensus treatment plans that describe therapy for moderate juvenile DM throughout the treatment course. These treatment plans can now be used clinically, and data collected prospectively regarding treatment effectiveness and toxicity. This will allow comparison of these treatment plans and facilitate the development of evidence-based treatment recommendations for moderate juvenile DM.

Original languageEnglish (US)
Pages (from-to)546-553
Number of pages8
JournalArthritis Care and Research
Volume64
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Rheumatology
Arthritis
Research
Therapeutics
Steroids
Juvenile dermatomyositis
Pediatrics

ASJC Scopus subject areas

  • Rheumatology

Cite this

Consensus treatments for moderate juvenile dermatomyositis : Beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. / Huber, Adam M.; Robinson, Angela B.; Reed, Ann M.; Abramson, Leslie; Bout-Tabaku, Sharon; Carrasco, Ruy; Curran, Megan; Feldman, Brian M.; Gewanter, Harry; Griffin, Thomas; Haines, Kathleen; Hoeltzel, Mark F.; Isgro, Josephine; Kahn, Philip; Lang, Bianca; Lawler, Patti; Shaham, Bracha; Schmeling, Heinrike; Scuccimarri, Rosie; Shishov, Michael; Stringer, Elizabeth; Wohrley, Julie; Ilowite, Norman Todd; Wallace, Carol.

In: Arthritis Care and Research, Vol. 64, No. 4, 04.2012, p. 546-553.

Research output: Contribution to journalArticle

Huber, AM, Robinson, AB, Reed, AM, Abramson, L, Bout-Tabaku, S, Carrasco, R, Curran, M, Feldman, BM, Gewanter, H, Griffin, T, Haines, K, Hoeltzel, MF, Isgro, J, Kahn, P, Lang, B, Lawler, P, Shaham, B, Schmeling, H, Scuccimarri, R, Shishov, M, Stringer, E, Wohrley, J, Ilowite, NT & Wallace, C 2012, 'Consensus treatments for moderate juvenile dermatomyositis: Beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference', Arthritis Care and Research, vol. 64, no. 4, pp. 546-553. https://doi.org/10.1002/acr.20695
Huber, Adam M. ; Robinson, Angela B. ; Reed, Ann M. ; Abramson, Leslie ; Bout-Tabaku, Sharon ; Carrasco, Ruy ; Curran, Megan ; Feldman, Brian M. ; Gewanter, Harry ; Griffin, Thomas ; Haines, Kathleen ; Hoeltzel, Mark F. ; Isgro, Josephine ; Kahn, Philip ; Lang, Bianca ; Lawler, Patti ; Shaham, Bracha ; Schmeling, Heinrike ; Scuccimarri, Rosie ; Shishov, Michael ; Stringer, Elizabeth ; Wohrley, Julie ; Ilowite, Norman Todd ; Wallace, Carol. / Consensus treatments for moderate juvenile dermatomyositis : Beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. In: Arthritis Care and Research. 2012 ; Vol. 64, No. 4. pp. 546-553.
@article{35403a1c27194e989fb3dac82c02776e,
title = "Consensus treatments for moderate juvenile dermatomyositis: Beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference",
abstract = "Objective. To use consensus methods and the considerable expertise contained within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) organization to extend the 3 previously developed treatment plans for moderate juvenile dermatomyositis (DM) to span the full course of treatment. Methods. A consensus meeting was held in Chicago on April 23-24, 2010, involving 30 pediatric rheumatologists and 4 lay participants. Nominal group technique was used to achieve consensus on treatment plans that represented typical management of moderate juvenile DM. A preconference survey of CARRA, completed by 151 (56{\%}) of 272 members, was used to provide additional guidance to the discussion. Results. Consensus was reached on timing and rate of steroid tapering, duration of steroid therapy, and actions to be taken if patients were unchanged, worsening, or experiencing medication side effects or disease complications. Of particular importance, a single consensus steroid taper was developed. Conclusion. We were able to develop consensus treatment plans that describe therapy for moderate juvenile DM throughout the treatment course. These treatment plans can now be used clinically, and data collected prospectively regarding treatment effectiveness and toxicity. This will allow comparison of these treatment plans and facilitate the development of evidence-based treatment recommendations for moderate juvenile DM.",
author = "Huber, {Adam M.} and Robinson, {Angela B.} and Reed, {Ann M.} and Leslie Abramson and Sharon Bout-Tabaku and Ruy Carrasco and Megan Curran and Feldman, {Brian M.} and Harry Gewanter and Thomas Griffin and Kathleen Haines and Hoeltzel, {Mark F.} and Josephine Isgro and Philip Kahn and Bianca Lang and Patti Lawler and Bracha Shaham and Heinrike Schmeling and Rosie Scuccimarri and Michael Shishov and Elizabeth Stringer and Julie Wohrley and Ilowite, {Norman Todd} and Carol Wallace",
year = "2012",
month = "4",
doi = "10.1002/acr.20695",
language = "English (US)",
volume = "64",
pages = "546--553",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Consensus treatments for moderate juvenile dermatomyositis

T2 - Beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference

AU - Huber, Adam M.

AU - Robinson, Angela B.

AU - Reed, Ann M.

AU - Abramson, Leslie

AU - Bout-Tabaku, Sharon

AU - Carrasco, Ruy

AU - Curran, Megan

AU - Feldman, Brian M.

AU - Gewanter, Harry

AU - Griffin, Thomas

AU - Haines, Kathleen

AU - Hoeltzel, Mark F.

AU - Isgro, Josephine

AU - Kahn, Philip

AU - Lang, Bianca

AU - Lawler, Patti

AU - Shaham, Bracha

AU - Schmeling, Heinrike

AU - Scuccimarri, Rosie

AU - Shishov, Michael

AU - Stringer, Elizabeth

AU - Wohrley, Julie

AU - Ilowite, Norman Todd

AU - Wallace, Carol

PY - 2012/4

Y1 - 2012/4

N2 - Objective. To use consensus methods and the considerable expertise contained within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) organization to extend the 3 previously developed treatment plans for moderate juvenile dermatomyositis (DM) to span the full course of treatment. Methods. A consensus meeting was held in Chicago on April 23-24, 2010, involving 30 pediatric rheumatologists and 4 lay participants. Nominal group technique was used to achieve consensus on treatment plans that represented typical management of moderate juvenile DM. A preconference survey of CARRA, completed by 151 (56%) of 272 members, was used to provide additional guidance to the discussion. Results. Consensus was reached on timing and rate of steroid tapering, duration of steroid therapy, and actions to be taken if patients were unchanged, worsening, or experiencing medication side effects or disease complications. Of particular importance, a single consensus steroid taper was developed. Conclusion. We were able to develop consensus treatment plans that describe therapy for moderate juvenile DM throughout the treatment course. These treatment plans can now be used clinically, and data collected prospectively regarding treatment effectiveness and toxicity. This will allow comparison of these treatment plans and facilitate the development of evidence-based treatment recommendations for moderate juvenile DM.

AB - Objective. To use consensus methods and the considerable expertise contained within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) organization to extend the 3 previously developed treatment plans for moderate juvenile dermatomyositis (DM) to span the full course of treatment. Methods. A consensus meeting was held in Chicago on April 23-24, 2010, involving 30 pediatric rheumatologists and 4 lay participants. Nominal group technique was used to achieve consensus on treatment plans that represented typical management of moderate juvenile DM. A preconference survey of CARRA, completed by 151 (56%) of 272 members, was used to provide additional guidance to the discussion. Results. Consensus was reached on timing and rate of steroid tapering, duration of steroid therapy, and actions to be taken if patients were unchanged, worsening, or experiencing medication side effects or disease complications. Of particular importance, a single consensus steroid taper was developed. Conclusion. We were able to develop consensus treatment plans that describe therapy for moderate juvenile DM throughout the treatment course. These treatment plans can now be used clinically, and data collected prospectively regarding treatment effectiveness and toxicity. This will allow comparison of these treatment plans and facilitate the development of evidence-based treatment recommendations for moderate juvenile DM.

UR - http://www.scopus.com/inward/record.url?scp=84859764386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859764386&partnerID=8YFLogxK

U2 - 10.1002/acr.20695

DO - 10.1002/acr.20695

M3 - Article

C2 - 22076847

AN - SCOPUS:84859764386

VL - 64

SP - 546

EP - 553

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 4

ER -